Nicox SA, an international ophthalmology company, announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. A total of 691 patients were enrolled in the trial. NCX 470, Nicox
